FI925342A - Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi - Google Patents
Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi Download PDFInfo
- Publication number
- FI925342A FI925342A FI925342A FI925342A FI925342A FI 925342 A FI925342 A FI 925342A FI 925342 A FI925342 A FI 925342A FI 925342 A FI925342 A FI 925342A FI 925342 A FI925342 A FI 925342A
- Authority
- FI
- Finland
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- fluorophenyl
- ethyl
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53195490A | 1990-06-01 | 1990-06-01 | |
US53195490 | 1990-06-01 | ||
PCT/US1991/003036 WO1991018602A1 (en) | 1990-06-01 | 1991-04-30 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
US9103036 | 1991-04-30 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI925342A true FI925342A (fi) | 1992-11-25 |
FI925342A0 FI925342A0 (fi) | 1992-11-25 |
FI95370B FI95370B (fi) | 1995-10-13 |
FI95370C FI95370C (fi) | 1996-01-25 |
Family
ID=24119769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI925342A FI95370C (fi) | 1990-06-01 | 1992-11-25 | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi |
Country Status (15)
Country | Link |
---|---|
US (6) | US5134149A (fi) |
EP (1) | EP0531410B1 (fi) |
JP (1) | JP2869512B2 (fi) |
KR (1) | KR100211713B1 (fi) |
AT (1) | ATE114467T1 (fi) |
AU (1) | AU652759B2 (fi) |
CA (1) | CA2083698C (fi) |
DE (1) | DE69105501T2 (fi) |
DK (1) | DK0531410T3 (fi) |
ES (1) | ES2067937T3 (fi) |
FI (1) | FI95370C (fi) |
GR (1) | GR3015087T3 (fi) |
HU (1) | HU213271B (fi) |
NO (1) | NO179250C (fi) |
WO (1) | WO1991018602A1 (fi) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018602A1 (en) * | 1990-06-01 | 1991-12-12 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
GB9718712D0 (en) | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
KR100258018B1 (ko) * | 1997-12-23 | 2000-07-01 | 유승필 | 티클로피딘과 은행잎 추출물을 함유한 약제조성물 |
US20050261341A1 (en) * | 1998-03-13 | 2005-11-24 | Aventis Pharmaceuticals Inc. | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
TWI249526B (en) * | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6713627B2 (en) | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
SE9801516D0 (sv) * | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907/4-Piperidinemethanol derivatives for autism |
GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6277864B1 (en) | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
HUP0202145A3 (en) * | 1998-08-28 | 2003-02-28 | Aventis Pharmaceuticals Inc Br | The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
CN1160333C (zh) * | 1998-10-14 | 2004-08-04 | 阿温蒂斯药物公司 | 哌啶甲醇的酯和它们作为5ht2a受体拮抗剂mdl110907药物前体的用途 |
WO2000035423A1 (en) * | 1998-12-16 | 2000-06-22 | Aventis Pharmaceuticals Inc. | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
FR2787328A1 (fr) | 1998-12-22 | 2000-06-23 | Sanofi Sa | Utilisation d'un antagoniste des recepteurs 5ht2a pour la preparation de medicaments utiles dans le traitement des ronflements et du syndrome de haute resistance ou de resistance des voies aeriennes superieures |
GB9901147D0 (en) | 1999-01-19 | 1999-03-10 | Merck Sharp & Dohme | Therapeutic agents |
US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
DE60032489T2 (de) * | 1999-07-16 | 2007-10-11 | Aventis Pharmaceuticals Inc. | SCHWEFELSÄURE MONO-Ä3- (ä1-Ä2-(4-FLUORO-PHENYL)-ETHYLÜ-PIPERIDIN-4-YLü -HYDROXY-METHYL)-2-METHOXY-PHENYLÜESTER |
DE19939756A1 (de) | 1999-08-21 | 2001-02-22 | Merck Patent Gmbh | Piperidinalkohole |
DK1113015T3 (da) * | 1999-12-29 | 2004-12-13 | Pfizer Prod Inc | Optisk aktive 3-[(2-piperazinyl-phenyl)methyl]-1-[4-(trifluormethyl)-phenyl]-2-pyrrolidinonforbindelser som 5-HT1D-receptor-selektive antagonister |
RU2257384C2 (ru) * | 2000-02-29 | 2005-07-27 | Мицубиси Фарма Корпорейшн | Новые производные циклического амида |
GB0007907D0 (en) | 2000-03-31 | 2000-05-17 | Merck Sharp & Dohme | Therapeutic agents |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
US20030177248A1 (en) * | 2001-09-05 | 2003-09-18 | International Business Machines Corporation | Apparatus and method for providing access rights information on computer accessible content |
DE60311822T2 (de) * | 2002-07-19 | 2007-12-06 | Biovitrum Ab | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen |
RU2340333C2 (ru) * | 2002-08-15 | 2008-12-10 | Вайет | Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции |
US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
CA2548917C (en) | 2003-12-11 | 2014-09-23 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20060069124A1 (en) * | 2004-09-07 | 2006-03-30 | Rao P S | Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases |
KR100941527B1 (ko) | 2004-09-30 | 2010-02-10 | 에프. 호프만-라 로슈 아게 | 인지 장애를 치료하기 위한 조성물 |
EP2305645B1 (en) | 2008-06-20 | 2012-05-16 | NHWA Pharma.corporation | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent |
EP2714624B1 (en) | 2011-05-23 | 2017-12-27 | Sanofi | Process for the preparation of deuterated compounds containing n-alkyl groups |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833775A (en) * | 1951-08-17 | 1958-05-06 | Schering Corp | Substituted piperidines |
US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
US3394131A (en) * | 1961-04-26 | 1968-07-23 | Squibb & Sons Inc | Acid esters of phenothiazine |
US3194733A (en) * | 1961-04-26 | 1965-07-13 | Olin Mathicson Chemical Corp | Phenothiazine compositions and method of treating mental disorders |
GB1316424A (en) * | 1969-05-20 | 1973-05-09 | Minnesota 3M Lab Ltd | Alpha-hydroxy-substituted-phenyl-alpha-2-piperidyl-methanols and process for the preparation thereof |
US3655676A (en) * | 1970-11-19 | 1972-04-11 | Smith Kline French Lab | 4-hydroxy-3-hydroxymethylphenyl-2-piperidinylcarbinols |
US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
US4701461A (en) * | 1983-03-21 | 1987-10-20 | Usv Pharmaceutical Corporation | Substituted cyclic amines |
US4623728A (en) * | 1984-07-26 | 1986-11-18 | Pfizer Inc. | Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents |
US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
CA1280421C (en) * | 1985-07-02 | 1991-02-19 | Albert A. Carr | 1,4-disubstituted piperidinyl derivatives |
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US4762842A (en) * | 1985-10-01 | 1988-08-09 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
IT1205685B (it) * | 1987-05-26 | 1989-03-31 | Erregierre Spa | Processo per la preparazione di alfa-(alchilfenil)-4-(idrossi difenilmetil)-1-piperidina butanolo |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
ZA888572B (en) * | 1987-11-23 | 1989-08-30 | Merrell Dow Pharma | Treatment of fibromyalgia |
JPH02138214A (ja) * | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | 不安を治療する方法 |
US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
US5064838A (en) * | 1988-01-21 | 1991-11-12 | Merrell Dow Pharmaceuticals | 1,4-disubstituted-piperidinyl compounds as pain relievers |
EP0325063B1 (en) * | 1988-01-21 | 1994-03-09 | Merrell Dow Pharmaceuticals Inc. | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia |
AU629535B2 (en) * | 1988-02-10 | 1992-10-08 | A.H. Robins Company, Incorporated | N-substituted-arylalkyl and arylalkylene aminoheterocyclics as cardiovascular antihistaminic and antisecretory agents |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
AU629534B2 (en) * | 1988-02-24 | 1992-10-08 | A.H. Robins Company, Incorporated | New methods and related compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5070087A (en) * | 1989-05-08 | 1991-12-03 | A. H. Robins Company, Incorporated | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents |
US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
WO1991018602A1 (en) * | 1990-06-01 | 1991-12-12 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
-
1991
- 1991-04-30 WO PCT/US1991/003036 patent/WO1991018602A1/en active IP Right Grant
- 1991-04-30 DK DK91910548.6T patent/DK0531410T3/da active
- 1991-04-30 DE DE69105501T patent/DE69105501T2/de not_active Expired - Lifetime
- 1991-04-30 AU AU79509/91A patent/AU652759B2/en not_active Expired
- 1991-04-30 EP EP91910548A patent/EP0531410B1/en not_active Expired - Lifetime
- 1991-04-30 CA CA002083698A patent/CA2083698C/en not_active Expired - Lifetime
- 1991-04-30 AT AT91910548T patent/ATE114467T1/de not_active IP Right Cessation
- 1991-04-30 KR KR1019920703050A patent/KR100211713B1/ko not_active IP Right Cessation
- 1991-04-30 HU HU9203779A patent/HU213271B/hu unknown
- 1991-04-30 ES ES91910548T patent/ES2067937T3/es not_active Expired - Lifetime
- 1991-04-30 JP JP3510161A patent/JP2869512B2/ja not_active Expired - Lifetime
- 1991-07-26 US US07/736,194 patent/US5134149A/en not_active Expired - Lifetime
-
1992
- 1992-11-25 FI FI925342A patent/FI95370C/fi active
- 1992-11-30 NO NO924619A patent/NO179250C/no not_active IP Right Cessation
-
1995
- 1995-01-13 US US08/372,694 patent/US5561144A/en not_active Expired - Lifetime
- 1995-02-16 GR GR950400305T patent/GR3015087T3/el unknown
- 1995-06-07 US US08/485,700 patent/US5700813A/en not_active Expired - Lifetime
- 1995-06-07 US US08/485,701 patent/US5700812A/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,538 patent/US5721249A/en not_active Expired - Lifetime
-
1997
- 1997-10-02 US US08/942,629 patent/US5874445A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HUT64745A (en) | 1994-02-28 |
NO924619D0 (no) | 1992-11-30 |
HU9203779D0 (en) | 1993-03-29 |
JPH05507482A (ja) | 1993-10-28 |
AU7950991A (en) | 1991-12-31 |
ATE114467T1 (de) | 1994-12-15 |
WO1991018602A1 (en) | 1991-12-12 |
CA2083698A1 (en) | 1991-12-02 |
EP0531410A1 (en) | 1993-03-17 |
AU652759B2 (en) | 1994-09-08 |
CA2083698C (en) | 1997-11-04 |
NO924619L (no) | 1992-11-30 |
KR930700103A (ko) | 1993-03-13 |
JP2869512B2 (ja) | 1999-03-10 |
EP0531410B1 (en) | 1994-11-30 |
US5874445A (en) | 1999-02-23 |
KR100211713B1 (ko) | 1999-08-02 |
NO179250B (no) | 1996-05-28 |
EP0531410A4 (en) | 1993-05-26 |
US5721249A (en) | 1998-02-24 |
HU213271B (en) | 1997-04-28 |
GR3015087T3 (en) | 1995-05-31 |
US5561144A (en) | 1996-10-01 |
DE69105501T2 (de) | 1995-04-13 |
US5700812A (en) | 1997-12-23 |
FI95370B (fi) | 1995-10-13 |
FI95370C (fi) | 1996-01-25 |
FI925342A0 (fi) | 1992-11-25 |
US5134149A (en) | 1992-07-28 |
DK0531410T3 (da) | 1995-01-30 |
ES2067937T3 (es) | 1995-04-01 |
NO179250C (no) | 1996-09-04 |
US5700813A (en) | 1997-12-23 |
DE69105501D1 (de) | 1995-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI925342A (fi) | Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi | |
TR199801180T2 (xx) | Aneljestik etkiye sahip yeni bile�ikler. | |
GEP20002298B (en) | Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment | |
DE69330823D1 (en) | Thiacyclische piperidinylderivate | |
UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
DE69637050D1 (de) | Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer | |
DE69424777T2 (de) | 3,4-diarylchromane zur behandlung von dermatitis | |
GR1000419B (el) | Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου. | |
AU682166B2 (en) | Synergising association having an antagonist effect on NK1 and NK2 receptors | |
PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
AR006281A1 (es) | Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares | |
AU655958B2 (en) | Use of quisqualate-receptor antagonists for treating Parkinson's disease | |
TR199801184T2 (xx) | Analjezik tesirli yeni bile�ikler. | |
UA41326C2 (uk) | Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань | |
HRP20080389A2 (en) | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS | |
DE69429447T2 (de) | Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 7 infektionen | |
YU15301A (sh) | PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA | |
MX9701528A (es) | Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer. | |
MY110416A (en) | Composition for the treatment of schizophrenia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: AVENTIS INC. Free format text: AVENTIS INC. |
|
PC | Transfer of assignment of patent |
Owner name: AVENTISUB II INC. Free format text: AVENTISUB II INC. |